← Back to Search

MRI Sequence

MR Fingerprinting for Disease

N/A
Waitlist Available
Led By William Hyslop, MD, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The study will include English-speaking patients that are already scheduled to undergo a clinical MRI for diagnostic purposes.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately following mri completion, within approximately 5 minutes
Awards & highlights

Study Summary

Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations. One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image "weighted" by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately following mri completion, within approximately 5 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately following mri completion, within approximately 5 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of Patients With Visible Region of Interest (Imaging Visibility)

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention
All participants will receive the investigational MR Fingerprinting sequence.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MR Fingerprinting
2019
N/A
~70

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,506 Previous Clinical Trials
4,190,539 Total Patients Enrolled
4 Trials studying Disease
34,180 Patients Enrolled for Disease
William Hyslop, MD, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025